MedTrace Logo

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT03994549 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-12-02

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo within each cohort.

Conditions

  • Healthy

Interventions

DRUG

Dual GLP-1/GLP-2 Receptor agonists

Eight ascending doses of ZP7570

Sponsors & Collaborators

Principal Investigators

  • Ulrike Hövelmann, MD · Profil Neuss, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-14
Primary Completion
2020-11-02
Completion
2020-11-02

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03994549 on ClinicalTrials.gov